文献速递免疫规划

口服活肺炎支原体疫苗接种可在小鼠模型中诱导呼吸道保护性免疫

Oral vaccination with live Mycoplasma pneumoniae elicits a respiratory protective immunity in a murine model.
PubMed 文献 · Vaccine · 2025-07-02

研究以C57BL/6 J小鼠经口灌胃接种活肺炎支原体,评估短期安全性与免疫效果。口服接种可能实现肠道清除、限制全身播散且肠道与肺组织无致病性;末次给药后3周或15周经鼻感染,肺部病原负荷降低、肺炎症减轻、肺IL-1β与TNF-α分泌减少,并引发系统性支原体特异性IgG、IgM及肺黏膜IgA升高与Th1、Th2、CTL克隆扩增。

要点

  • 小鼠经口接种活肺炎支原体后,肠道清除、全身播散受限,肠道与肺组织无致病性。
  • 末次给药后3周或15周经鼻感染,肺部病原负荷降低、肺炎症减轻、肺IL-1β与TNF-α分泌减少。
  • 再暴露引发回忆应答:系统性支原体特异性IgG、IgM及肺黏膜IgA升高,Th1、Th2、CTL克隆扩增。

核心结论

  • 作者认为口服接种是开发肺炎支原体疫苗的有前景途径。

研究设计与样本

  • C57BL/6 J小鼠经口灌胃接种活肺炎支原体,评估短期安全性与免疫效果,并在末次给药后3周或15周经鼻进行细菌感染。

主要发现

  • 口服接种可能表现为肠道清除、全身播散受限,肠道与肺组织无致病性。
  • 口服接种有效降低肺部病原负荷、减轻肺炎症、减少肺IL-1β与TNF-α分泌(末次给药后3周或15周经鼻感染)。
  • 再暴露触发强烈回忆应答:系统性支原体特异性IgG与IgM升高、肺黏膜IgA升高,伴Th1、Th2与CTL克隆扩增。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vaccine development targeting Mycoplasma pneumoniae began in the 1960s, but achieving safe and effective immunization is still challenging. Careful consideration of the immunization pathway is one of the critical aspects of vaccine development. In this investigation, C57BL/6 J mice were intragastrically vaccinated with live M. pneumoniae, and the short-term safety and resultant immune effects were evaluated. Oral administration likely demonstrated intestinal clearance with restricted systemic dissemination and no tissue pathogenicity in both the intestinal and pulmonary tracts. Furthermore, the oral vaccination with live M. pneumoniae effectively reduced the pathogen burden in the lung, alleviated pulmonary inflammation, and reduced the pulmonary secretion of IL-1β and TNF-α after intranasal bacterial infection 3 or 15 weeks after the last dose. Moreover, Airway exposure to M. pneumoniae in live pathogen intragastric vaccinated mice triggered robust recall responses, marked by the elevation of systemic mycoplasma-specific IgG and IgM, alongside pulmonary mucosal IgA, paralleled by clonal expansion of Th1, Th2, and CTL. In conclusion, oral delivery presents a promising route for developing M. pneumoniae vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Yu L, Chen C, He G, et al. Oral vaccination with live Mycoplasma pneumoniae elicits a respiratory protective immunity in a murine model. Vaccine. 2025. PMID: 40609261. doi:10.1016/j.vaccine.2025.127460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。